A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
This study is trying to compare how well a medicine called talquetamab works when it's given with two other medicines called daratumumab and pomalidomide, versus giving it with just the daratumumab. They want to see if this combination works better than another treatment using daratumumab with pomalidomide and dexamethasone.
This study is trying to compare how well a medicine called talquetamab works when it's given with two other medicines called daratumumab and pomalidomide, versus giving it with just the daratumumab. They want to see if this combination works better than another treatment using daratumumab with pomalidomide and dexamethasone.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
